Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04030247 · ClinicalTrials.gov registry record · Phase 4
Impact of Plant Sterol Supplement on LDL-C Lowering in Low-to-Moderate Risk South Asian Patients
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT04030247: Completed Phase 4 study, sponsored by Stanford University.
NCT04030247 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04030247, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the incremental effectiveness of a twice daily plant sterol supplement in a population of South Asian patients who have low-to-moderate cardiovascular disease (CVD) risk.
Interventions
- DRUG Plant Sterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-01-06 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04030247
The ClinicalTrials.gov registry entry for NCT04030247 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Plant Sterol is the first listed.
NCT04030247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04030247 about?
NCT04030247 is a clinical study titled "Impact of Plant Sterol Supplement on LDL-C Lowering in Low-to-Moderate Risk South Asian Patients". The purpose of this study is to measure the incremental effectiveness of a twice daily plant sterol supplement in a population of South Asian patients who have low-to-moderate cardiovascular disease (CVD) risk.
What is the current status of trial NCT04030247?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2020-01-06. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT04030247?
The interventions under investigation include: Plant Sterol (DRUG).
Who is sponsoring clinical trial NCT04030247?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.